Inserm Equipe Angiogenèse Tumorale, Institut Curie, Centre de Recherche, Département Recherche Translationnelle, 26 rue d'Ulm, 75005, Paris, France.
BMC Cancer. 2013 May 20;13:246. doi: 10.1186/1471-2407-13-246.
The Follicle Stimulating Hormone receptor (FSHR) is expressed by the vascular endothelium in a wide range of human tumors. It was not determined however if FSHR is present in metastases which are responsible for the terminal illness.
We used immunohistochemistry based on a highly FSHR-specific monoclonal antibody to detect FSHR in cancer metastases from 6 major tumor types (lung, breast, prostate, colon, kidney, and leiomyosarcoma ) to 6 frequent locations (bone, liver, lymph node, brain, lung, and pleura) of 209 patients.
In 166 patients examined (79%), FSHR was expressed by blood vessels associated with metastatic tissue. FSHR-positive vessels were present in the interior of the tumors and some few millimeters outside, in the normally appearing tissue. In the interior of the metastases, the density of the FSHR-positive vessels was constant up to 7 mm, the maximum depth available in the analyzed sections. No significant differences were noticed between the density of FSHR-positive vessels inside vs. outside tumors for metastases from lung, breast, colon, and kidney cancers. In contrast, for prostate cancer metastases, the density of FSHR-positive vessels was about 3-fold higher at the exterior of the tumor compared to the interior. Among brain metastases, the density of FSHR-positive vessels was highest in lung and kidney cancer, and lowest in prostate and colon cancer. In metastases of breast cancer to the lung pleura, the percentage of blood vessels expressing FSHR was positively correlated with the progesterone receptor level, but not with either HER-2 or estrogen receptors. In normal tissues corresponding to the host organs for the analyzed metastases, obtained from patients not known to have cancer, FSHR staining was absent, with the exception of approx. 1% of the vessels in non tumoral temporal lobe epilepsy samples.
FSHR is expressed by the endothelium of blood vessels in the majority of metastatic tumors.
卵泡刺激素受体（FSHR）在广泛的人类肿瘤的血管内皮细胞中表达。然而，尚不清楚 FSHR 是否存在于导致终末期疾病的转移灶中。
我们使用基于高度特异性 FSHR 单克隆抗体的免疫组织化学方法，检测来自 6 种主要肿瘤类型（肺、乳腺、前列腺、结肠、肾和平滑肌肉瘤）的 6 种常见转移部位（骨、肝、淋巴结、脑、肺和胸膜）的 209 名患者的癌症转移灶中的 FSHR。
在检查的 166 名患者（79%）中，与转移性组织相关的血管表达 FSHR。FSHR 阳性血管存在于肿瘤内部和正常组织中几毫米之外。在转移灶内部，FSHR 阳性血管的密度在分析切片的最大深度 7mm 内保持恒定。在肺、乳腺、结肠和肾癌转移灶中，肿瘤内部与外部 FSHR 阳性血管的密度无显著差异。相比之下，在前列腺癌转移灶中，肿瘤外部的 FSHR 阳性血管密度约为内部的 3 倍。在脑转移灶中，FSHR 阳性血管的密度在肺癌和肾癌中最高，在前列腺癌和结肠癌中最低。在乳腺癌肺胸膜转移灶中，表达 FSHR 的血管比例与孕激素受体水平呈正相关，但与 HER-2 或雌激素受体无关。在来自未患癌症的患者的相应分析转移部位的正常组织中，除了大约 1%的非肿瘤性颞叶癫痫样本外，FSHR 染色均不存在。
FSHR 在大多数转移性肿瘤的血管内皮细胞中表达。
